Patents by Inventor Marie-Francoise Belin

Marie-Francoise Belin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190119339
    Abstract: A purified polypeptide, designated ULIP6, comprising the amino acid sequence SED ID No. 2 or an epitopic fragment of said polypeptide, comprising the sequence SEQ ID No. 4, is provided along with its nucleic acid sequences. In addition, antibodies to the polypeptide and methods of diagnosing paraneoplastic neurological syndromes and/or for the early diagnosis of the formation of cancerous tumors are also provided.
    Type: Application
    Filed: September 12, 2018
    Publication date: April 25, 2019
    Inventors: Michele AGUERA, Jean-Christophe ANTOINE, Marie-Francoise BELIN, Jerome HONNORAT, Veronique ROGEMOND
  • Patent number: 10087220
    Abstract: A purified polypeptide, designated ULIP6, comprising the amino acid sequence SEQ ID No. 2 or an epitopic fragment of said polypeptide, comprising the sequence SEQ ID No. 4, is provided along with its nucleic acid sequences. In addition, antibodies to the polypeptide and methods of diagnosing paraneoplastic neurological syndromes and/or for the early diagnosis of the formation of cancerous tumors are also provided.
    Type: Grant
    Filed: January 15, 2013
    Date of Patent: October 2, 2018
    Assignee: INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Michele Aguera, Jean-Christophe Antoine, Marie-Francoise Belin, Jerome Honnorat, Veronique Rogemond
  • Patent number: 8377645
    Abstract: A purified polypeptide, designated ULIP6, comprising the amino acid sequence SEQ ID No. 2 or an epitopic fragment of said polypeptide, comprising the sequence SEQ ID No. 4, is provided along with its nucleic acid sequences. In addition, antibodies to the polypeptide and methods of diagnosing paraneoplastic neurological syndromes and/or for the early diagnosis of the formation of cancerous tumors are also provided.
    Type: Grant
    Filed: February 11, 2008
    Date of Patent: February 19, 2013
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Michèle Aguera, Jean-Christophe Antoine, Marie-Françoise Belin, Jérôme Honnorat, Véronique Rogemond
  • Publication number: 20120027758
    Abstract: The invention relates to the use a BD16 and/or BB18 anti-CD100 antibody or of a chimeric or humanized or human form thereof, or a fragment thereof, for the therapy or diagnosis of a central nervous system disorder, more particularly a myelin disorder or a disease that affects oligodendrocytes, such as multiple sclerosis or HTLV-1 associated myelopathy or peripheral myelinating cells.
    Type: Application
    Filed: October 11, 2011
    Publication date: February 2, 2012
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Marie-Françoise Belin, Pascale Giraudon, Laurence Boumsell, Armand Bensussan
  • Patent number: 8067247
    Abstract: The invention relates to the use a BD16 and/or BB18 anti-CD100 antibody or of a chimeric or humanized or human form thereof, or a fragment thereof, for the therapy or diagnosis of a central nervous system disorder, more particularly a myelin disorder or a disease that affects oligodendrocytes, such as multiple sclerosis or HTLV-1 associated myelopathy or peripheral myelinating cells.
    Type: Grant
    Filed: February 2, 2004
    Date of Patent: November 29, 2011
    Assignee: Institut National de la Sante Et de la Recherche Medicale (INSERM)
    Inventors: Marie-Françoise Belin, Pascale Giraudon, Laurence Boumsell, Armand Bensussan
  • Patent number: 7820375
    Abstract: The invention concerns the use of at least a protein of the CRMP family, a polypeptide fragment or an active biological derivative thereof, a nucleotide sequence or sequence fragment coding for said protein, an antisense sequence capable of being specifically hybridized with a sequence with nucleotide-type encoding of said protein or an antibody directed against said protein for producing a medicine for treating diseases related to a dysfunction of the immune system. The invention also concerns a method for diagnosing an autoimmune pathology which consists in measuring the expression of a CRMP protein in the lymphocytes.
    Type: Grant
    Filed: September 9, 2002
    Date of Patent: October 26, 2010
    Assignee: Institut National de la Sante Et de la Recherche Medicale (Inserm)
    Inventors: Pascale Giraudon, Marie-Françoise Belin, Christophe Malcus, Pierre Colas, Jean-Christophe Antoine, Jérôme Honnorat
  • Publication number: 20080226636
    Abstract: A purified polypeptide, designated ULIP6, comprising the amino acid sequence SEQ ID No. 2 or an epitopic fragment of said polypeptide, comprising the sequence SEQ ID No. 4, is provided along with its nucleic acid sequences. In addition, antibodies to the polypeptide and methods of diagnosing paraneoplastic neurological syndromes and/or for the early diagnosis of the formation of cancerous tumors are also provided.
    Type: Application
    Filed: February 11, 2008
    Publication date: September 18, 2008
    Inventors: Michele Aguera, Jean-Christophe Antoine, Marie-Francoise Belin, Jerome Honnorat, Veronique Rogemond
  • Patent number: 7329499
    Abstract: The invention concerns a purified polypeptide, called ULIP6, comprising an amino acid sequence SEQ ID NO 2, the nucleic acid coding for said polypeptide, a non-coding sequence in 3? of said encoding sequence and their use in diagnosis and treatment of cancers and paraneoplastic neurological syndromes.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: February 12, 2008
    Assignee: Institut National de la Sante et de la Recherche Medicale (Inserm)
    Inventors: Michèle Aguera, Jean-Christophe Antoine, Marie-Françoise Belin, Jérôme Honnorat, Véronique Rogemond
  • Publication number: 20070117166
    Abstract: The invention relates to the use of proteins designated ULIP/POP in the diagnosis and therapy of cancers and paraneoplastic neurological syndromes.
    Type: Application
    Filed: December 20, 2006
    Publication date: May 24, 2007
    Inventors: Michele Aguera, Marie-Francoise Belin, Jerome Honnorat, Pappachan Kolattukudy, ThanhTam Quach, Tamara Byk, Andre Sobel, Dominique Aunis, Jean-Christophe Antoine
  • Patent number: 7183400
    Abstract: The invention concerns a purified polypeptide, biologically active polypeptide derivative or fragment of said purified polypeptide, comprising an amino acid sequence selected among SEQ.ID. No. 2, No. 4, No. 6 and No. 8.
    Type: Grant
    Filed: February 19, 1998
    Date of Patent: February 27, 2007
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Michèle Aguera, Marie-Françoise Belin, Jérôme Honnorat, Pappachan Kolattukudy, ThanhTam Quach, Tamara Byk, André Sobel, Dominique Aunis, Jean-Christophe Antoine
  • Publication number: 20060233793
    Abstract: The invention relates to the use a BD16 and/or BB18 anti-CD100 antibody or of a chimeric or humanized or human form thereof, or a fragment thereof, for the therapy or diagnosis of a central nervous system disorder, more particularly a myelin disorder or a disease that affects oligodendrocytes, such as multiple sclerosis or HTLV-1 associated myelopathy or peripheral myelinating cells.
    Type: Application
    Filed: February 2, 2004
    Publication date: October 19, 2006
    Inventors: Marie-Francoise Belin, Pascale Giraudon, Laurence Boumsell, Armand Bensussan
  • Publication number: 20050106143
    Abstract: The invention concerns the use of at least a protein of the CRMP family, a polypeptide fragment or an active biological derivative thereof, a nucleotide sequence or sequence fragment coding for said protein, an antisense sequence capable of being specifically hybridized with a sequence with nucleotide-type encoding of said protein or an antibody directed against said protein for producing a medicine for treating diseases related to a dysfunction of the immune system. The invention also concerns a method for diagnosing an autoimmune pathology which consists in measuring the expression of a CRMP protein in the lymphocytes.
    Type: Application
    Filed: September 9, 2002
    Publication date: May 19, 2005
    Inventors: Pascale Giraudon, Marie-Francoise Belin, Christophe Malcus, Pierre Colas, Jean-Christophe Antoine, Jerome Honnorat
  • Publication number: 20030176336
    Abstract: The invention concerns a purified polypeptide, called ULIP6, comprising an amino acid sequence SEQ ID NO 2, the nucleic acid coding for said polypeptide, a non-coding sequence in 3′ of said encoding sequence and their use in diagnosis and treatment of cancers and paraneoplastic neurological syndromes.
    Type: Application
    Filed: November 19, 2002
    Publication date: September 18, 2003
    Inventors: Michele Aguera, Jean-Christophe Antoine, Marie-Francoise Belin, Jerome Honnorat, Veronique Rogemond
  • Publication number: 20020119944
    Abstract: This invention relates to methods and compositions for the prevention or treatment of myelin disorders which involve modulating of Ulip/CRMP activity. In particular, a method for the prevention or treatment of myelin disorders is provided which comprises administering to a patient in need of such treatment a therapeutically effective amount of an agent which modulates Ulip/CRMP activity, and which can be a Ulip/CRMP protein, a nucleic acid coding for a Ulip/CRMP protein, an anti-sense sequence capable of specifically hybridizing with said nucleic acid, an antibody directed against the Ulip/CRMP protein, or an aptamer capable of binding said protein, and a pharmacologically acceptable carrier.
    Type: Application
    Filed: November 9, 2001
    Publication date: August 29, 2002
    Inventors: Michelle Aguera, Marie-Francoise Belin, Emmanuelle Charrier, Jerome Honorat, Damien Ricard, Veronique Rogemond